Accordingly, CDK12 has been described as a tumor suppressor protein in different types of human cancer, such as high-grade serous ovarian cancer, prostate cancer and TNBC, where CDK12 inactivating mutations are associated with high genomic instability and aggressive clinical behavior10–14. Here, CDK12 is linked to ovarian serous adenocarcinoma.